Product Description
Tamoxifen is a nonsteroidal antiestrogen that has found successful applications for each stage of breast cancer in the treatment of selected patients. Tamoxifen was originally introduced for the treatment of advanced disease in postmenopausal women; however, the drug is now also available for the palliative treatment of premenopausal women with estrogen receptor (ER) positive disease. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1582240/)
Mechanisms of Action: ARO Inhibitor,ER Agonist,ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Breast Cancer | Breast Carcinoma In Situ | Carcinoma in Situ | Ductal Breast Carcinoma | Ductal Carcinoma | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Vaginal Discharge | Hot Flashes | Injuries/wounds Unspecified
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Korea, Mexico, Netherlands, Russia, Singapore, Spain, Taiwan, Turkey, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Male Breast Cancer|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADEPT | P2 |
Recruiting |
Breast Cancer |
2026-09-01 |
|
| LALEAST | P2 |
Active, not recruiting |
Male Breast Cancer |
2026-05-01 |
|
| PATHWAY | P3 |
Active, not recruiting |
Breast Cancer |
2025-09-01 |
|
| I3Y-MC-JPCG | P2 |
Unknown Status |
Breast Cancer |
2024-12-30 |